Moderna Chalks Up Industry Milestone With mRNA Cancer Vaccine Efficacy Success
Executive Summary
Phase IIb KEYNOTE-942 study shows mRNA-4157/V940 paired with Keytruda reduces risk of recurrence and death in post-surgical melanoma patients compared with Keytruda alone.
You may also be interested in...
Could Moderna/Merck Cancer Vaccine Succeed Where Others Have Flopped?
The partners unveiled long-awaited proof-of-concept data for mRNA-4157 at the AACR meeting showing a statistically significant improvement in recurrence-free survival among melanoma patients.
With COVID Crash In Sight, Moderna’s Post-Pandemic Future Starts To Take Shape
The company reported a fourth quarter decline in SARS-CoV-2 vaccine sales and guided for sales of $5bn in 2023. It is looking ahead to filing for approval of its RSV vaccine.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.